Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilateral Intravitreal GS010 in G11778A ND4 Leber Hereditary Optic Neuropathy
2017-002187-40Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Jan 2018
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Leber hereditary optic neuropathy (LHON) comparing Bilateral GS010 with Placebo (2 arms). Primary endpoint: Best Corrected Visual Acuity in LogMAR at 1 Year. Started Jan 2018; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2017-002187-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002187-40.